Apricus Biosciences, Inc (APRI) to Release Earnings on Wednesday

Apricus Biosciences, Inc (NASDAQ:APRI) will be announcing its earnings results after the market closes on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Thursday, May 11th. The company reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by $0.21. During the same quarter last year, the firm posted ($0.50) EPS. On average, analysts expect Apricus Biosciences to post $-0.79 EPS for the current fiscal year and $0.37 EPS for the next fiscal year.

Shares of Apricus Biosciences, Inc (APRI) opened at 1.12 on Wednesday. The firm’s 50-day moving average is $1.07 and its 200 day moving average is $1.73. Apricus Biosciences, Inc has a 52-week low of $0.86 and a 52-week high of $4.94. The stock has a market capitalization of $14.30 million, a price-to-earnings ratio of 2.52 and a beta of 0.51.

A number of analysts have recently weighed in on APRI shares. Rodman & Renshaw started coverage on shares of Apricus Biosciences in a report on Wednesday, April 26th. They issued a “buy” rating on the stock. Zacks Investment Research downgraded shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th.

WARNING: “[[title]]” was originally reported by [[site]] and is the property of of [[site]]. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at [[permalink]].

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.